There is something particularly frustrating about cervical cancer — it kills approximately 350,000 women annually worldwide and is one of the most preventable cancers in existence. Gardasil 9 prevents 90% of cases when given before HPV exposure. Organized screening detects precancerous lesions before progression. In countries where both are available and accessible, cervical cancer has become rare. Globally it remains the fourth most common cancer in women, largely because of unequal vaccine and screening access. The 2026 clinical trial landscape reflects this tension: therapeutic trials for advanced disease in high-income contexts, and prevention and screening research for settings where Pap tests and colposcopy remain inaccessible. For women with recurrent or metastatic disease, the pipeline — tisotumab vedotin combinations, HPV-targeted TIL therapy with 10–15% complete response rates in pretreated patients, therapeutic vaccines — represents genuine change in what was until recently one of oncology's most treatment-resistant scenarios.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional or oncologist before making any medical decisions or considering participation in a clinical trial.
Summary
The standard of care for persistent, recurrent, or metastatic cervical cancer has changed twice in the past five years. Pembrolizumab plus chemotherapy became standard first-line for PD-L1 CPS ≥1 disease in 2021 (KEYNOTE-826: OS 24.4 vs. 16.5 months vs. chemotherapy). Tisotumab vedotin (Tivdak) was approved second-line in 2023 after innovaTV 301 showed OS 11.5 vs. 9.5 months over investigator-choice chemotherapy. The 2026 pipeline builds directly on these approvals: tisotumab vedotin plus pembrolizumab combinations in Phase 3, HPV-specific TIL therapy with complete response rates of 10–15% in heavily pretreated patients, and therapeutic HPV vaccines targeting E6 and E7 oncoproteins. Early-stage trials are testing de-escalation strategies to reduce treatment-related morbidity in younger patients with low-risk disease.
ClinicalMetric Analysis
- Tisotumab vedotin + pembrolizumab is mechanistically coherent — the ADC delivers direct tumor killing while the checkpoint inhibitor generates systemic immune response. Tissue factor is highly and specifically expressed in cervical cancer, which limits bystander ADC-mediated cytotoxicity and reduces the immunosuppressive cell death that would compete with PD-1 inhibition. The innovaTV 205 combination data showing ORRs above 40% in first-line — before the combination was tested against pembrolizumab-alone in a randomized design — set expectations that the randomized Phase 3 program now needs to confirm. Whether TV-pembro is superior to pembrolizumab + chemotherapy (the current standard) is the key unanswered question.
- HPV-specific TIL therapy's 10–15% complete response rate in heavily pretreated cervical cancer is meaningful — but the manufacturing window and treatment burden make patient selection critical. TIL therapy requires 4–6 weeks of ex vivo expansion, followed by lymphodepleting chemotherapy and high-dose IL-2 — a regimen requiring excellent performance status and no active organ compromise. In cervical cancer patients who have already received platinum-based chemotherapy and pembrolizumab, performance status and organ reserve are frequently limiting. Patients considering TIL therapy should discuss candidacy realistically with centers that have treated at least 20+ patients with this approach, not just those offering it as a clinical option.
- De-escalation trials for early cervical cancer reflect documented quality-of-life consequences that oncology hasn't historically measured rigorously. Lymphedema, sexual dysfunction, bowel dysfunction, and urinary incontinence affect 40–60% of cervical cancer survivors at 5 years, with data from prospective cohort studies now quantifying the magnitude. Young patients cured at 35 with decades of treatment-related dysfunction represent a different risk-benefit calculation than older patients. De-escalation trials need validated QOL instruments and long-term follow-up as primary co-endpoints — not just disease-free survival — to capture the full clinical picture.
Tisotumab Vedotin (Tivdak) Combination Trials
Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), which is highly expressed in cervical cancer. It delivers monomethyl auristatin E (MMAE), a cytotoxin, directly to TF-expressing tumor cells. After innovaTV 301 demonstrated improved overall survival over chemotherapy in second-line recurrent cervical cancer, trials in 2026 are evaluating:
- Tisotumab vedotin + pembrolizumab in first-line metastatic disease (innovaTV 205 expansion cohorts)
- Tisotumab vedotin + carboplatin combination regimens in platinum-eligible populations
- ADC sequencing — optimal treatment sequence after prior pembrolizumab failure
- Biomarker studies — TF expression level as a predictive marker for response
The main safety concern with tisotumab vedotin is ocular toxicity (conjunctivitis, keratitis). Eye care protocols — lubricating drops and cold compresses during infusion — are now standard; trials are testing modified protocols to further reduce this risk.
Immunotherapy: Checkpoint Inhibitors and Beyond
Pembrolizumab (Keytruda) became the standard first-line addition to chemotherapy for PD-L1 CPS ≥1 recurrent/metastatic cervical cancer following KEYNOTE-826. Cemiplimab (Libtayo) is approved as monotherapy for second-line after platinum. The 2026 trial landscape is testing:
- Durvalumab + concurrent chemoradiation for locally advanced disease (CALLA trial follow-up and expansion)
- PD-L1 inhibitors for PD-L1 CPS <1 populations — where benefit has been unclear
- LAG-3 + PD-1 dual checkpoint blockade in checkpoint-refractory disease
- TIGIT inhibitors in combination with anti-PD-1 for immune-cold tumors
HPV-Targeted Cell Therapies and Therapeutic Vaccines
Because cervical cancer is driven by HPV oncoprotein expression (E6 and E7), the tumor presents HPV-derived peptides on its surface — making it a target for HPV-specific T-cell therapies unlike most solid tumors where the antigen is not so clearly defined.
TIL (Tumor-Infiltrating Lymphocyte) Therapy
The NCI Surgery Branch's TIL therapy — expanded tumor-infiltrating T-cells, reinfused after lymphodepletion — has shown dramatic responses in HPV-positive cervical cancer. Complete response rates of 10–15% in heavily pretreated patients are extraordinary for recurrent metastatic disease. Iovance Biotherapeutics is conducting Phase 3 TIL trials for cervical cancer. Eligibility typically requires adequate organ function and performance status after 1–2 prior lines of therapy.
Therapeutic HPV Vaccines
Unlike preventive HPV vaccines (Gardasil 9), therapeutic vaccines aim to generate immune responses against established HPV infection or tumor. Candidates in 2026 trials include:
- ISA101 (SLP HPV-16 peptide vaccine) — combined with pembrolizumab in KEYNOTE-A18 extension cohorts
- mRNA-based HPV vaccines (Moderna's mRNA-4157 platform adapted for HPV E6/E7 neoantigen targets)
- DNA vaccines (VGX-3100 in combination with immunotherapy for CIN3 and early cervical cancer)
Early-Stage: Fertility-Sparing and De-Escalation Trials
For women diagnosed with early-stage cervical cancer (Stage IB1–IB2), an active area of research addresses whether standard radical hysterectomy over-treats low-risk disease:
- Simple hysterectomy vs. radical hysterectomy in Stage IB1 ≤2cm tumors (ConCerv and similar trials)
- Fertility-sparing trachelectomy in young patients with early-stage disease — trials assessing oncological equivalence and fertility outcomes
- Neoadjuvant chemotherapy to downstage locally advanced disease before fertility-preserving surgery
Who Can Join a Cervical Cancer Trial?
Requirements vary significantly by trial stage and type, but common criteria for recurrent/metastatic disease trials include:
- Histologically confirmed cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma)
- ECOG performance status 0–1 (ambulatory, able to carry out light work)
- Prior platinum-based chemotherapy (for second-line trials)
- Measurable disease by RECIST 1.1 criteria
- Adequate hematologic, hepatic, and renal function
- No active autoimmune disease (for immunotherapy trials)
PD-L1 expression (CPS score) is required for some pembrolizumab trials but not for ADC or TIL trials. Fresh or archival tumor biopsy is typically required for biomarker analysis.
Browse Recruiting Trials
ClinicalMetric indexes recruiting cervical cancer studies from ClinicalTrials.gov, updated daily.
Search Cervical Cancer Trials →How Cervical Cancer Treatment Changed Between 2021 and 2023
Before 2021, recurrent or metastatic cervical cancer was treated with platinum-based chemotherapy — cisplatin or carboplatin plus paclitaxel, with bevacizumab added after GOG 240 showed a 3.7-month survival benefit in 2014. Response rates hovered around 30–50%; median overall survival was around 13–17 months. Patients who progressed after first-line had limited options.
KEYNOTE-826 changed that. In this Phase 3 randomized trial of 617 patients, adding pembrolizumab to chemotherapy (with or without bevacizumab) improved overall survival from 16.5 to 24.4 months in PD-L1 CPS ≥1 patients — a 40% reduction in the risk of death. Progression-free survival improved from 8.2 to 10.4 months. In PD-L1 CPS ≥10 patients, the benefit was even larger: median OS 28.4 vs. 16.8 months. Pembrolizumab received FDA approval for this indication in October 2021.
innovaTV 301 followed in 2023. Tisotumab vedotin — the antibody-drug conjugate targeting tissue factor — was compared to investigator-choice chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed) in second-line recurrent disease. OS improved from 9.5 to 11.5 months; the overall response rate was 17.8% vs. 5.2%. This made tisotumab vedotin the first second-line drug approved specifically for cervical cancer. The 2026 trial landscape is now trying to build on both approvals and extend benefit to patients who have progressed through both.
What Participation in a Cervical Cancer Trial Actually Looks Like
Trial protocols vary enormously depending on the treatment type — TIL therapy requires a surgical procedure to harvest tumor tissue, while a checkpoint inhibitor trial might require only IV infusions every three weeks. Here is what patients typically encounter across the main trial categories:
- ADC combination trials (tisotumab vedotin + pembrolizumab): IV infusion every 3 weeks, clinic visits lasting 3–6 hours per cycle, mandatory eye care protocol (lubricating drops, cold compresses), regular ophthalmic assessments. Neuropathy, alopecia, and eye irritation are the main expected side effects. Treatment continues until progression or intolerable toxicity.
- TIL therapy trials: These are intensive. Tumor biopsy is performed first to harvest T-cells. Cells are expanded ex vivo over 5–6 weeks. Patients then undergo lymphodepleting chemotherapy (usually fludarabine and cyclophosphamide), followed by TIL infusion and high-dose IL-2. Hospitalization of 2–3 weeks is required. The potential upside — durable complete responses in 10–15% of patients — is extraordinary for this disease setting. It is not appropriate for patients with poor performance status or significant organ dysfunction.
- Therapeutic vaccine trials: Generally outpatient, with injections at several-week intervals. Side effects are typically mild — injection site reactions, flu-like symptoms after dosing. Many vaccine trials are testing combination with pembrolizumab or other checkpoint inhibitors. Eligibility usually requires measurable or assessable disease.
- Fertility-sparing surgery trials: For early-stage patients considering trachelectomy. These involve standard surgical evaluation, pre-operative imaging, and post-surgical oncologic and fertility follow-up. Long-term monitoring of recurrence rates and reproductive outcomes is built into the protocol.
Trial duration varies from 6 months to several years. Post-treatment follow-up is typically 2–5 years from enrollment. Most academic cancer centers offering cervical cancer trials can assist with travel coordination for out-of-town patients, and many trials cover travel and accommodation expenses.
Access, Screening, and the Prevention Gap
Cervical cancer is the only common gynecologic malignancy that is largely preventable — yet it kills more women per year than uterine or vaginal cancer combined, almost entirely because preventive interventions are not equitably distributed. In the United States, cervical cancer incidence has declined by more than 70% since organized Pap smear screening began in the 1950s. The HPV vaccine has reduced HPV 16/18 infections by over 80% in vaccinated populations. In high-income countries with both vaccination programs and screening infrastructure, cervical cancer has become uncommon.
In low- and middle-income countries (LMICs), where approximately 90% of cervical cancer deaths occur, neither intervention is reliably available. Vaccine cold chain requirements, cytology laboratory infrastructure for Pap testing, and colposcopy referral capacity remain barriers at population scale. WHO's 90-70-90 strategy — 90% of girls vaccinated by age 15, 70% of women screened by age 35, 90% of women with cervical disease treated — sets the global targets but implementation has been uneven.
Clinical trials in LMICs in 2026 are focused on point-of-care HPV DNA testing (screen-and-treat without referral), visual inspection with acetic acid (VIA) as a lower-resource screening alternative, and self-sampling HPV programs to extend reach beyond clinical settings. These trials are no less important than the pembrolizumab combination studies; they address the population segment where the burden is greatest.
Frequently Asked Questions
Can I join a cervical cancer trial if I have already received pembrolizumab?
Yes, many trials specifically enroll patients who have progressed after prior checkpoint inhibitor therapy. These include ADC trials, TIL therapy trials, and trials testing novel targets like TIGIT or LAG-3 in immune-refractory disease. Prior pembrolizumab does not categorically exclude you; the protocol will specify an acceptable washout period (usually 4–6 weeks from last dose).
Does my tumor need to be HPV-positive to qualify?
Most cervical cancers are HPV-associated, but HPV status requirements vary by trial. TIL therapy and therapeutic vaccine trials targeting HPV E6/E7 typically require confirmed HPV-positive disease. ADC trials (tisotumab vedotin) require high TF expression, which is assessed separately from HPV status. For checkpoint inhibitor trials, PD-L1 CPS score is the key biomarker, not HPV status directly.
Is there a clinical trial option for Stage IVB cervical cancer?
Stage IVB (distant metastatic) disease is the primary enrollment population for first-line combination trials. KEYNOTE-826 and its successors enrolled patients with Stage IVB or recurrent disease not amenable to curative-intent surgery or radiation. If you have been diagnosed with Stage IVB disease and have adequate performance status and organ function, you are likely eligible to be evaluated for multiple trial options at an academic cancer center.